

Devidas Menon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4393720/publications.pdf>

Version: 2024-02-01

64
papers

1,477
citations

331670

21
h-index

345221

36
g-index

68
all docs

68
docs citations

68
times ranked

1774
citing authors

#	ARTICLE	IF	CITATIONS
1	Funding the Unfunda ^b le. <i>Pharmacoeconomics</i> , 2010, 28, 113-142.	3.3	120
2	Engaging the public in priority ^a -setting for health technology assessment: findings from a citizens ^a -jury. <i>Health Expectations</i> , 2008, 11, 282-293.	2.6	97
3	The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond. <i>Value in Health</i> , 2008, 11, 771-783.	0.3	95
4	Predicting Survival after Liver Transplantation Based on Pre-Transplant MELD Score: a Systematic Review of the Literature. <i>PLoS ONE</i> , 2013, 8, e80661.	2.5	86
5	Role of patient and public participation in health technology assessment and coverage decisions. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 75-89.	1.4	73
6	Access with Evidence Development Schemes. <i>Pharmacoeconomics</i> , 2010, 28, 143-152.	3.3	71
7	Health Technology Funding Decision-Making Processes Around the World. <i>Pharmacoeconomics</i> , 2011, 29, 475-495.	3.3	64
8	Health Technology Assessment in Canada: 20 Years Strong?. <i>Value in Health</i> , 2009, 12, S14-S19.	0.3	48
9	Endoscopic treatments for Barrett's esophagus: a systematic review of safety and effectiveness compared to esophagectomy. <i>BMC Gastroenterology</i> , 2010, 10, 111.	2.0	45
10	Access to Drugs for Cancer. <i>Canadian Journal of Public Health</i> , 2005, 96, 454-458.	2.3	43
11	The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. <i>Pharmacoeconomics</i> , 1999, 15, 459-468.	3.3	42
12	Inter-Provincial Variation in Government Drug Formularies. <i>Canadian Journal of Public Health</i> , 2001, 92, 307-312.	2.3	42
13	Regional Cerebral Blood Flow in Patients with Aneurysms: Estimation by Xenon 133 Inhalation. <i>Canadian Journal of Neurological Sciences</i> , 1978, 5, 301-305.	0.5	39
14	Priority-setting for healthcare: Who, how, and is it fair?. <i>Health Policy</i> , 2007, 84, 220-233.	3.0	37
15	Principles of Design of Access with Evidence Development Approaches. <i>Pharmacoeconomics</i> , 2010, 28, 109-111.	3.3	37
16	Challenges with implementing malaria rapid diagnostic tests at primary care facilities in a Ghanaian district: a qualitative study. <i>Malaria Journal</i> , 2016, 15, 126.	2.3	36
17	To Fund or Not to Fund. <i>Pharmacoeconomics</i> , 2011, 29, 771-780.	3.3	30
18	Pharmaceutical Cost Control In Canada: Does It Work?. <i>Health Affairs</i> , 2001, 20, 92-103.	5.2	27

#	ARTICLE	IF	CITATIONS
19	HEALTH TECHNOLOGY ASSESSMENT IN CANADA A Decade in Review. International Journal of Technology Assessment in Health Care, 2000, 16, 896-902.	0.5	26
20	Assisted reproductive technologies (ARTs): Evaluation of evidence to support public policy development. Reproductive Health, 2014, 11, 76.	3.1	26
21	Incorporating patient preferences into clinical trial design: Results of the Opinions of Patients on Treatment Implications of New Studies (OPTIONS) project. American Heart Journal, 2015, 169, 122-131.e22.	2.7	24
22	Involving Patients in Reducing Decision Uncertainties Around Orphan and Ultra-Orphan Drugs: A Rare Opportunity?. Patient, 2015, 8, 29-39.	2.7	23
23	Palliative care in the home: a scoping review of study quality, primary outcomes, and thematic component analysis. BMC Palliative Care, 2018, 17, 41.	1.8	23
24	Exploring patient and family involvement in the lifecycle of an orphan drug: a scoping review. Orphanet Journal of Rare Diseases, 2017, 12, 188.	2.7	21
25	Defining the role of the public in Health Technology Assessment (HTA) and HTA-informed decision-making processes. International Journal of Technology Assessment in Health Care, 2020, 36, 87-95.	0.5	21
26	Patient Portal Implementation and Uptake: Qualitative Comparative Case Study. Journal of Medical Internet Research, 2020, 22, e18973.	4.3	20
27	Evaluation of Cerebral Blood Flow in Arteriovenous Malformations by the Xenon 133 Inhalation Method. Canadian Journal of Neurological Sciences, 1979, 6, 411-416.	0.5	18
28	Capturing the Impact of Patient Portals Based on the Quadruple Aim and Benefits Evaluation Frameworks: Scoping Review. Journal of Medical Internet Research, 2020, 22, e24568.	4.3	15
29	Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. Canadian Urological Association Journal, 2013, 2, 1.	0.6	14
30	Determining social values for resource allocation decision-making in cancer care: a Canadian experiment. Journal of Cancer Policy, 2014, 2, 81-88.	1.4	14
31	Developing a Patient-Directed Policy Framework for Managing Orphan and Ultra-Orphan Drugs Throughout Their Lifecycle. Patient, 2015, 8, 103-117.	2.7	14
32	Effectiveness of home-based pulmonary rehabilitation programs for patients with chronic obstructive pulmonary disease (COPD): systematic review. BMC Health Services Research, 2022, 22, 557.	2.2	14
33	An international survey of assisted reproductive technologies (ARTs) policies and the effects of these policies on costs, utilization, and health outcomes. Health Policy, 2014, 116, 238-263.	3.0	13
34	Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?. Healthcare Policy, 2015, 11, 15-32.	0.6	13
35	Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?. Healthcare Policy, 2015, 11, 15-32.	0.6	13
36	Robot-assisted coronary artery bypass surgery: a systematic review and meta-analysis of comparative studies. Canadian Journal of Surgery, 2020, 63, E491-E508.	1.2	12

#	ARTICLE	IF	CITATIONS
37	HTA decision-making for drugs for rare diseases: comparison of processes across countries. Orphanet Journal of Rare Diseases, 2022, 17, .	2.7	12
38	Tracing the Decisions That Shaped the Development of MyChart, an Electronic Patient Portal in Alberta, Canada: Historical Research Study. Journal of Medical Internet Research, 2020, 22, e17505.	4.3	11
39	The role of surgeons in identifying emerging technologies for health technology assessment. Canadian Journal of Surgery, 2010, 53, 86-92.	1.2	11
40	Access with Evidence Development: An Approach to Introducing Promising New Technologies into Healthcare. Healthcare Management Forum, 2011, 24, 42-48.	1.4	7
41	Quality of life of older adults in two contrasting neighbourhoods in Accra, Ghana. Social Science and Medicine, 2021, 270, 113659.	3.8	7
42	Health technology assessment: the journey continues. Cmaj, 2015, 187, E19-E20.	2.0	6
43	Explicating social values for resource allocation decisions on new cancer technologies: We, the jury, findâ. Journal of Cancer Policy, 2017, 14, 5-10.	1.4	6
44	Engagement of Canadian Patients with Rare Diseases and Their Families in the Lifecycle of Therapy: A Qualitative Study. Patient, 2018, 11, 353-359.	2.7	6
45	A checklist for managed access programmes for reimbursement coâdesigned by Canadian patients and caregivers. Health Expectations, 2018, 21, 973-980.	2.6	6
46	The Development of a Health Technology Assessment Program: The Case of Alberta. International Journal of Technology Assessment in Health Care, 1995, 11, 93-101.	0.5	5
47	Bridging the âKnow-DoâGap in Healthcare Priority-Setting: What Role Has Academic Research Played?. Healthcare Management Forum, 2005, 18, 26-32.	1.4	5
48	A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds. Healthcare Policy, 2015, 10, 24-46.	0.6	5
49	Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada. Orphanet Journal of Rare Diseases, 2019, 14, 127.	2.7	4
50	Health, quality of life, and wellbeing of older slum dwellers in sub-Saharan Africa: A scoping review. Global Public Health, 2020, 16, 1-19.	2.0	4
51	Cerebral protection devices for use during carotid artery angioplasty with stenting: A health technology assessment. International Journal of Technology Assessment in Health Care, 2006, 22, 119-129.	0.5	3
52	Assisted Reproductive Technologies in Alberta: An Economic Analysis to Inform Policy Decision-Making. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 1122-1130.	0.7	3
53	A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds. Healthcare Policy, 2015, 10, 24-46.	0.6	3
54	Decision-Making on New Non-Drug Health Technologies (NDTs) by Hospitals and Health Authorities in Canada. Healthcare Policy, 2019, 15, 82-94.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Effectiveness of remote home monitoring for patients with Chronic Obstructive Pulmonary Disease (COPD): systematic review. BMC Health Services Research, 2022, 22, 646.	2.2	3
56	An Assessment of Health Technology Assessment in Canada. Canadian Journal of Public Health, 2000, 91, 120-120.	2.3	2
57	The Medical Devices Special Access Program in Canada: A Scoping Study. Healthcare Policy, 2018, 13, 40-57.	0.6	2
58	The Introduction of New Non-Drug Health Technologies (NDTs) into Canadian Healthcare Institutions: Opportunities and Challenges. Healthcare Policy, 2019, 15, 95-106.	0.6	2
59	“Our Home Is a Muddy Structure” Perceptions of Housing and Health Risks Among Older Adults in Contrasting Neighborhoods in Ghana. Frontiers in Public Health, 2021, 9, 650861.	2.7	2
60	DEFINING ELIGIBILITY CRITERIA FOR FUNDING POLICIES AROUND IN VITRO FERTILIZATION. International Journal of Technology Assessment in Health Care, 2015, 31, 426-433.	0.5	1
61	Ultra-orphan drugs: can we afford the price. Expert Opinion on Orphan Drugs, 2017, 5, 611-612.	0.8	1
62	Transparency in Reimbursement Decisions: In Whose Best Interest?. Pharmacoeconomics, 2014, 32, 725-727.	3.3	0
63	Introduction of a new health technology into a provincial health system. Healthcare Management Forum, 2015, 28, 210-214.	1.4	0
64	Health Insurance Exemptions for Older Ghanaians: Stakeholder Perspectives on Challenges Confronting an Ambitious Policy. Journal of Aging and Social Policy, 2022, , 1-19.	1.6	0